Skip to main content
OpenTrials
Completed

NCT Number: NCT00995917

A Pilot Study of Acupoint Injection for Primary Dysmenorrhea

Many women, particularly adolescent women, suffer from painful menstrual cramps, medically referred to as dysmenorrhea. Common treatments for menstrual cramps are non-steroidal anti-inflammatory drugs and oral contraceptives, but both have side effects that limit their use. Injection of vitamin K into an acupuncture point has been used as treatment for dysmenorrhea at the Obstetrics & Gynecology Hospital in Shanghai, China since at least 1985. More research is needed on the effectiveness of this treatment and its acceptability to different women. The objective of this study is to examine the feasibility and effectiveness of acupoint injection of vitamin K1 for the treatment of severe primary dysmenorrhea in the United States. Twenty participants will be randomized to receive either 1) vitamin K1 injection into an acupuncture point at the start of their menstrual cycle followed by a saline injection in a non-acupuncture point two months later or 2) saline injection in a non-acupuncture point followed by vitamin K1 injection into an acupuncture point two months later. The primary outcome measure will be change in pain intensity measured before and after each treatment. Data on other menstrual symptoms will be collected by telephone or a web-based survey. Three additional participants will be recruited to receive vitamin K1 injection into an acupuncture point and have blood samples drawn before and after injection to determine absorption of vitamin K1. The aims of the study are to collect preliminary data on the efficacy and safety of vitamin K1 injected in an acupoint for the treatment of severe primary dysmenorrhea; assess the feasibility and acceptability of the treatment among U.S. women; and test the blood absorption of vitamin K1 following acupoint injection treatment.

The investigators hypothesize that:

1. Vitamin K1 acupoint injection is a safe treatment for women with menstrual pain. 2. Vitamin K1 acupoint injection reduces menstrual pain more than placebo saline injection does. 3. The treatment of vitamin K1 acupoint injection is acceptable to U.S. women. 4. Vitamin K1 is absorbed into the blood thru acupoint injection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–25 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Mount Zion Outpatient Unit

San Francisco, California, 94115, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Young women age 18-25
  • Severe primary dysmenorrhea (defined as severe, recurrent painful periods for 6 months or more, that are not due to any other diagnosis, and that have not been relieved, or have been only partially relieved by any other treatment)
  • Nulliparous
  • English speaking
  • No acute or chronic conditions diagnosed or suspected
  • Not on hormonal contraceptives
  • Regular menstrual cycles for at least 6 months
  • Has a working phone or pager

Exclusion criteria

  • Use of hormonal contraceptives, or intra-uterine device
  • Pregnancy
  • Dysmenorrhea due to any other suspected or recognized causes
  • History of abdominal surgery
  • Participation in other concomitant therapy for acute or chronic pain
  • Current treatment with anti-coagulant drugs for any reason
  • Previous treatment with vitamin K acupoint injection
  • Plans to be out of area during next 5 months
  • Under age 18
  • Known allergy to Vitamin K.

Treatment and study plan

Vitamin K acupoint injection

Other

Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.

Saline injection

Other

Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.

Primary outcomes

  1. self-reported pain

    Time frame: 3-5 months

Secondary outcomes

  1. medications used during menstrual cycle

    Time frame: 3-5 months

  2. activity restriction

    Time frame: 3-5 months

  3. vitamin K content in blood

    Time frame: 1-2 months

  4. Cox retrospective symptom scale

    Time frame: 3-5 months

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Registry information

Official study title

A Randomized, Crossover, Pilot Trial of the Feasibility and Safety of Acupoint Injection of Vitamin K for Treatment of Primary Dysmenorrhea

Acronym: DAT

Important dates

Study start
2009
Primary completion
2011
Study completion
2011
First posted
Oct 16, 2009
Registry last updated
Apr 20, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.